{"id":"pegylated-interferon-alpha-2a-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Depression and mood changes"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Nausea"},{"rate":"10-20","effect":"Alopecia"},{"rate":"5-15","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated interferon alpha 2a is a long-acting form of interferon that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory effects including activation of natural killer cells and upregulation of antiviral proteins. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes guanosine pools, reducing viral replication. The combination provides synergistic antiviral activity against hepatitis C virus.","oneSentence":"Pegylated interferon alpha 2a activates innate immune responses against viral infections, while ribavirin inhibits viral RNA synthesis, together providing antiviral activity primarily against hepatitis C virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:14.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT00680173","phase":"PHASE4","title":"Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT02377856","phase":"PHASE4","title":"Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2007-06","conditions":"Acute Hepatitis C","enrollment":20},{"nctId":"NCT01686789","phase":"PHASE4","title":"Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4","status":"COMPLETED","sponsor":"King Abdulaziz Medical City","startDate":"2011-01","conditions":"Chronic Hepatitis C Virus","enrollment":181},{"nctId":"NCT01471574","phase":"PHASE3","title":"Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C, Genotype 1","enrollment":549},{"nctId":"NCT00774397","phase":"PHASE2","title":"Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":719},{"nctId":"NCT00874770","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-06","conditions":"Hepatitis C Infection","enrollment":74},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT02112630","phase":"NA","title":"Boceprevir in End Stage Renal Disease (ESRD)","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-05","conditions":"Hepatitis C Infection, End Stage Renal Disease","enrollment":""},{"nctId":"NCT00984620","phase":"PHASE2","title":"Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-09","conditions":"Hepatitis C","enrollment":160},{"nctId":"NCT00630084","phase":"PHASE4","title":"Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2006-08","conditions":"Chronic Hepatitis C, Neoplasms","enrollment":120},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01459913","phase":"PHASE3","title":"Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT00433069","phase":"PHASE2","title":"Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":5},{"nctId":"NCT01467479","phase":"PHASE3","title":"A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-12","conditions":"Hepatitis C","enrollment":185},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT00540345","phase":"PHASE4","title":"Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2006-10","conditions":"Chronic Hepatitis C","enrollment":300},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00535847","phase":"PHASE2","title":"A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-10","conditions":"Hepatitis C","enrollment":117},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT02027493","phase":"NA","title":"Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":46},{"nctId":"NCT00580801","phase":"PHASE2","title":"An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-01","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT00502099","phase":"PHASE4","title":"Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","status":"COMPLETED","sponsor":"Amr Hafez","startDate":"2006-01","conditions":"Hepatitis C","enrollment":217},{"nctId":"NCT01024894","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy","status":"UNKNOWN","sponsor":"Cytheris SA","startDate":"2009-01","conditions":"Hepatitis C","enrollment":15},{"nctId":"NCT01025297","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone","status":"UNKNOWN","sponsor":"Cytheris SA","startDate":"2008-07","conditions":"Hepatitis C","enrollment":18},{"nctId":"NCT01517308","phase":"PHASE3","title":"24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C","status":"WITHDRAWN","sponsor":"Federico II University","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00203606","phase":"PHASE4","title":"Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2004-01","conditions":"Hepatitis c","enrollment":66},{"nctId":"NCT00085917","phase":"PHASE2","title":"Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-06","conditions":"Hepatitis C, HIV Infections","enrollment":29},{"nctId":"NCT00192569","phase":"PHASE4","title":"Australian Trial in Acute Hepatitis C","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-07","conditions":"Hepatitis C","enrollment":167},{"nctId":"NCT01327729","phase":"PHASE2, PHASE3","title":"Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C","status":"UNKNOWN","sponsor":"BioGeneric Pharma","startDate":"2010-11","conditions":"Self Efficacy, Hepatitis C","enrollment":300},{"nctId":"NCT00629824","phase":"PHASE4","title":"Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2007-02","conditions":"Chronic Hepatitis C","enrollment":250},{"nctId":"NCT01137383","phase":"PHASE3","title":"Pegaferon and Ribavirin for Hepatitis C","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2007-12","conditions":"Hepatitis C","enrollment":108},{"nctId":"NCT00553930","phase":"PHASE4","title":"Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"2007-11","conditions":"Hepatitis C, Chronic, HIV Infections","enrollment":71},{"nctId":"NCT00084279","phase":"PHASE2","title":"CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)","status":"COMPLETED","sponsor":"InterMune","startDate":"2004-04","conditions":"Chronic Hepatitis C","enrollment":81},{"nctId":"NCT00909129","phase":"NA","title":"Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"","conditions":"Human Immunodeficiency Virus, Chronic Hepatitis C","enrollment":25},{"nctId":"NCT00527540","phase":"PHASE3","title":"Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tehran Hepatitis Center","startDate":"2007-02","conditions":"Hepatitis C","enrollment":60},{"nctId":"NCT00629967","phase":"PHASE4","title":"A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2005-04","conditions":"Chronic Hepatitis C, Genotype","enrollment":200},{"nctId":"NCT00088504","phase":"PHASE2","title":"Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2004-07","conditions":"Hepatitis C, Hepatitis","enrollment":315},{"nctId":"NCT00196586","phase":"PHASE2","title":"Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2003-04","conditions":"HIV Infections, Chronic Hepatitis C","enrollment":75},{"nctId":"NCT00241618","phase":"PHASE4","title":"Timing and Duration of Acute Hepatitis C Treatment","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2002-01","conditions":"Hepatitis C","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEGASYS®"],"phase":"marketed","status":"active","brandName":"pegylated interferon alpha 2a, ribavirin","genericName":"pegylated interferon alpha 2a, ribavirin","companyName":"Kaohsiung Medical University Chung-Ho Memorial Hospital","companyId":"kaohsiung-medical-university-chung-ho-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alpha 2a activates innate immune responses against viral infections, while ribavirin inhibits viral RNA synthesis, together providing antiviral activity primarily against hepatitis C virus. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}